A New Point of Intervention in Respiratory Virus Protection
N001 is Ness Therapeutics Inc. lead program, a self-administered intranasal prophylactic designed to stop transmission and prevent progression of respiratory virus infections by acting directly at the upper airway.
Unlike pathogen-specific approaches that depend on identifying the virus in advance, or therapeutics that are applied after infection has occurred, N001 is being developed as a host-directed, airway-focused intervention intended for prevention and early post-exposure use.
Intranasal Delivery
N001 is administered directly to the upper airway, placing the intervention exactly where respiratory viruses first make contact. No injection, no clinical setting, self-administered and designed for real-world use.
Local Antiviral Defence
N001 is designed to activate the host's own antiviral defenses at the point of entry. By working through the body's innate immune response, it does not rely on prior knowledge of the infecting virus.
Early Protection
N001 targets the critical window before infection takes hold, designed to reduce early viral replication and support protection against onward transmission and progression to more serious disease.
Deployable at Scale
N001 is designed to be self-administered and deployable without a clinical setting, making it accessible across populations and scalable to the demands of both routine and emergency respiratory virus response.
Preclinical and Clinical Findings Supporting the Program
The rationale for N001 is supported by a body of preclinical and clinical work showing broad antiviral protection, reduced lung disease severity, accelerated viral clearance, reduced inflammatory biomarkers, and a transmission signal in exposed contacts.
Advancing Toward Clinical Readiness
N001 is in IND/CTA-enabling development, with key foundational work already established and current enabling activities concluding. Ness is advancing the program through formulation, preclinical studies, toxicology, and regulatory preparation, with the objective of achieving clinical readiness and the longer-term goal of clinical translation toward a Phase 2-ready asset.
2026
IND/CTA-enabling package and submission readiness
Finalize CMC and formulation, complete preclinical safety package, and assemble IND/CTA dossier
2026/2027
Phase I safety +
PD signal
First-in-human intranasal study to confirm safety and target engagement
2027
Phase 2 endpoint
execution
Demonstrate clinical effect on transmission and early disease control in defined populations
2028
Pivotal
Ready
Scale manufacturing and align regulatory path for pivotal studies and partnering optionality
Broad Relevance Across Respiratory Protection Settings
Because N001 is host-directed and does not depend on a pathogen-specific match, it may be relevant across seasonal circulation, outbreak response, and broader preparedness contexts where immediate, deployable protection is critical.
Program and Company Updates
Sign up to receive updates on N001's development milestones, regulatory progress, and key program announcements as Ness Therapeutics Inc. advances toward clinical readiness.
